Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So for all those "Non-Believers" out there about the infomercials and the mytrak being an HM3 product...my previous 2 posts are proof.
Response Expo 2011, May 3rd - 5th http://www.responsemagazine.com/response-expo/attending-companies-0
MTT, how is it that every time you say you can't "Google" www.trymytrak.com it doesn't work for you, but when I TRY TO GOOGLE IT< it works completely fine for me? I'm a contractor in Afghanistan and still have abilities to google it and find it just fine.
Hey "Smacktheask", have you really done your DD on this stock/company? If you have, you will see that in the past 2 months alone there were multiple days where there was no movement on this stock. I'm just saying...
Just because there is a STOP on otcmarkets.com does not have that much affect on this stock at this particular moment in time!
And where is the suspected top? I got in because an associate I trade with herd from someone else that read your post....and advised to get into ADSV. I'm enjoying the profits, but where is the possible ceiling on this thing?
GLER NEWS NICE IMHO!
GLER NEWZ OUT!!!
providing the link would be sufficient for me. Because i don't think there is one that exists!
Most of the 500m Float is locked up and with that being the case, it will take a PR to allow this bad boy to move...but when it does, I hope everyone in it has their seatbelts on! JMHO.
Market Value1 $5,540,358 a/o Mar 31, 2011
Shares Outstanding 1,420,604,598 a/o Jun 30, 2010
Float 502,061,566 a/o Aug 02, 2010
Authorized Shares 1,500,000,000 a/o Dec 31, 2009
SGDH Golden Cross in the making!!!
BMOD to see +24 again today, JMHO!!!
BMOD NEWZ Biomoda announces positive results from lung cancer diagnostic test study
Comtex News Network "Datamonitor"
Mar 31, 2011 (Datamonitor via COMTEX) --
Biomoda, Inc., a cancer diagnostics company, has announced top-line results of its pilot study for lung cancer which shows significant evidence of CyPath's ability to discriminate between cancer and non-cancer groups based on sputum samples collected in a non-invasive manner.
Sensitivity of the assay was determined at 77% with specificity at 58% accounting for patient factors, and an overall accuracy of 81.3% in the ability to correctly classify groups of study participants into the cancer or high-risk cohorts.
A Receiver Operating Characteristic (ROC) analysis of the sensitivity and specificity was shown to have an associated "p value" of less than .001, resulting in a statistically significant finding of CyPath's ability to discriminate between high-risk and cancer groups.
The pilot study analyzed sputum samples from two cohorts: the high-risk cohort of 102 military veterans who smoked more than 20 "pack years," were asymptomatic for lung cancer and/or had not been diagnosed with lung cancer, and a control group of 26 patients diagnosed with primary lung cancer who had not started treatment.
Each participant provided a deep-lung sputum sample which was processed onto 12 slides, representing about 600,000 cells from each individual, a small percentage of the total number of cells collected in each sample. The slides were immersed in the CyPath labeling solution and viewed under a fluorescent microscope for the presence of fluorescing cells, which represent positive findings.
Quantitative measurements of the fluorescence on the CyPath-labeled sample slides and other patient metrics were statistically analyzed to determine the predictive accuracy of the molecular marker technology.
The high-risk cohort included individuals who had multiple risk factors, including heavy smoking, compromised pulmonary systems and other lung diseases. CyPath appears to bind to both cancerous and dysplastic, or precancerous, cells. However, this study did not include morphological analysis of red cells, and differentiation between dysplastic cells and cancer cells was not part of the pilot study.
Biomoda is conducting research now to define the cell matrices for quantitative measurement and increase CyPath's ability to not only identify lung cancer but to stage the disease by identifying all cells labeled with CyPath in a sample.
"The results demonstrate that CyPath is a significant new biomarker for lung cancer that can be optimized for use as an inexpensive, noninvasive lung cancer diagnostic for large at-risk populations," Biomoda CEO Maria Zannes said.
Forbes Riley's success off of 1 item...
PYBX news Con-X Construction Ltd. Update Regarding Ongoing Operations in Victoria B.C. and Saudi Arabia
Marketwire "Press Releases"
VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- 03/30/11 --
Con-X Construction Ltd. a wholly owned subsidiary of Playbox (US) Inc. (PYBX), has been working as a contractor to Scansa Construction Ltd for 18 months on a large scale housing development in Victoria B.C. called Kettle Creek Station. (www.kettlecreekstation.com) The project is a green eco minded neo traditional development incorporating geo thermal and granite kitchens for a starting price of $340,000. The planned 400 new homes are about 25% complete and the project is ongoing.
Con-X Construction Ltd is proud to be a part of this development and will draw on their experience on this project for the similar 152 home project outside of Vancouver B.C. for Sarra Homes.
Con-X Management is closely monitoring the situation in the Middle East and is continuing to assist with the Young Saudi Housing planning. This project was initiated in 2008 in conjunction with the Royal Family to deal with the 38% of the 25 million Saudis under the age of 14 years old. With the median age of 24.9 years old (for males 26 years female: 23.4 years) the situation has long-term contract possibilities. The current signed Contracts are nearing closure and Con-X expects to have signed new contracts by the end of April.
PYBX NEWS Con-X Construction Ltd. Update Regarding Ongoing Operations in Victoria B.C. and Saudi Arabia
Marketwire "Press Releases"
VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- 03/30/11 --
Con-X Construction Ltd. a wholly owned subsidiary of Playbox (US) Inc. (PYBX), has been working as a contractor to Scansa Construction Ltd for 18 months on a large scale housing development in Victoria B.C. called Kettle Creek Station. (www.kettlecreekstation.com) The project is a green eco minded neo traditional development incorporating geo thermal and granite kitchens for a starting price of $340,000. The planned 400 new homes are about 25% complete and the project is ongoing.
Con-X Construction Ltd is proud to be a part of this development and will draw on their experience on this project for the similar 152 home project outside of Vancouver B.C. for Sarra Homes.
Con-X Management is closely monitoring the situation in the Middle East and is continuing to assist with the Young Saudi Housing planning. This project was initiated in 2008 in conjunction with the Royal Family to deal with the 38% of the 25 million Saudis under the age of 14 years old. With the median age of 24.9 years old (for males 26 years female: 23.4 years) the situation has long-term contract possibilities. The current signed Contracts are nearing closure and Con-X expects to have signed new contracts by the end of April.
ITLI very nice vol and THIN!!!
ITLI movin' right up there! nice profits!!!
ITLI easy runner very thin
ITLI runnin up 400% very THIN as well
ITLI WOW what a fast filler!!!
No one is ignoring anything. Could the pps fall, yes. It did in September of last year. And then it bounced right back up to .0085+ and then leveled off to it's current level. Will some investors dump on the bid to get rid of shares if a PR does not come out by Thursday, very possible. I'm not denying that one bit. Will I be there to scoop up as many of those shares at that cheaper pps, yes. Could I screw myself by doing that? Could that be a possibility? Would a company use a name like Forbes' and misrepresent her like that? The answers to those ?'s are yes, those things could happen. Do I personally think that will happen, not to the drastic point that you are stating in your post. The pps could conceivably fall to around .0015 (+/- .0005) due to investors dumping on the bid due to no PR by 31st March. But this being a PINK/OTC stock...they are not held to "Normal Rules" like a small-mid cap company. In pinkie land anything is possible. JMHO
You are telling me nothing I do not know (2 days left till Q1). But I will say this, just because nothing has been PR'd does NOT mean that this company is a complete failure, it's not. They might have encountered other legal issues with any of the products (production, distribution, etc.). Anything is possible. And I firmly believe that even if the PPS falls, that is because the investors didn't feel like waiting...and they were all willing to sell for what ever price they can get...due to lack of patience. Do with as you will, I will what I can go continue to accumulate and strengthen my position even more so.
GLTA
How can you say:
EFIR NEWS and up 25% with HUGE BUYS
EFIR moving on news up 25% with NICE VOLUME!!!
EFIR running on HUGE NEWS!
SYMD up 120% on HUGE NEWZ!!!
Pathfinder Cells Demonstrate Ability to Regenerate Damaged Tissue and Restore Pancreatic Function in a Diabetic Mouse Model
PR Newswire "Press Releases US - English"
CAMBRIDGE, Mass., March 29, 2011 /PRNewswire/ -- Pathfinder, LLC, a private biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage ("Pathfinder"), today announced publication of promising preclinical data demonstrating that the Company's unique cell-based therapy is able to completely reverse diabetes in a mouse model. The results of the study, which will be printed in the April issue of Rejuvenation Research and available currently online, are the first to describe the Company's proprietary Pathfinder Cells ("PCs"), which stimulate regeneration of damaged tissues without the cells themselves being incorporated into the newly generated tissue.
"Though preliminary, the robustness of these results is very encouraging," stated Paul G. Shiels, Ph.D., University of Glasgow, Glasgow, United Kingdom. "With only two treatments with PCs, just days after induction of diabetes, we were able to quickly regenerate critically damaged pancreatic tissue, restoring and maintaining normal glucose levels and healthy body weight. Importantly, these results enhance our understanding of the mechanisms of self-repair elicited by PCs, which may represent a novel cell therapy-based approach to treating diseases marked by tissue damage and loss of organ function."
Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder said, "We are pleased to share our preliminary findings for this exciting new cell-based technology. We will continue to focus our efforts on elucidating the mechanism by which PCs stimulate tissue regeneration, as well as explore the potential use of such therapy in treating diseases with high unmet need such as diabetes, cardiac ischemia, and renal reperfusion injury."
The efficacy of PC treatment was examined using the common streptozotocin (STZ)-induced diabetic mouse model. At three and ten days following administration of STZ, which destroys insulin-producing beta-cells, 1.5 million human or rat pancreas-derived PCs were injected into mice intravenously. As early as day nine, animals treated with rat or human PCs had significantly lower blood glucose than control animals (p0.01). Animals in the control group became profoundly diabetic within one week following STZ administration, while PC-treated mice showed a progressive reduction in blood glucose, achieving normal levels by day 39 and maintaining these levels with no further treatment through day 89, at which point the study was terminated. Concurrent with the restoration of normal glucose levels, PC-treated animals recovered from an initial loss of body mass and maintained normal body weight for the remainder of the study.
Immunohistochemical analyses of animal tissues confirmed that PC treatment lead to regeneration of pancreatic beta-cells and formation of functional islets, which displayed normal architecture. Further examination determined that the regenerated islets consisted overwhelmingly of mouse cells, and to a much lesser extent, donor PCs (0.05-0.18%). The few PCs present in the islet tissue were diffused throughout sections, indicating that the PCs themselves do not form islet-like structures in vivo. Importantly, this strongly suggests that PCs activate mechanism(s) in the host that drive pancreatic islet regeneration, but which are not capable of initiating such repair in the absence of PCs.
Dr. Franklin concluded, "These data indicate the feasibility of using PCs to stimulate the regeneration of critically damaged adult tissue. The further development of PCs as a vehicle for regenerative medicine offers exciting prospects for future therapies."
All the Q's seem to be running
All the Q's seem to be running
XMDCQ up 171% with nice buys!
XMDCQ running up 114%
GRPS HUGE VOl and mvoing VERY NICELY
GRPS moving huge volume today!!!
GRPS up 34% and moving on news with EXCELLENT vol
GRPS news and it's up 36%
MCLS? anyone know anything about it? They just got PR released about an FDA approval for some cerebral bypass surgery. Any thoughts?
PRXZ moving nicely with .005's print
PRXZ nice thin lv2 with good vol!!!